Bandages removed from paws of bobcat burned in Eaton Fire
A bobcat found dehydrated and burned on all four paws during the Eaton Fire in January has made several steps forward in its recovery, officials said recently.
The female bobcat was found in Sierra Madre as the deadly and destructive wildfire raged through the hillsides and nearby communities.
'Our veterinary and wildlife teams cared for her over the coming weeks, changing the bandages on her paws regularly (under sedation) and nursing her back to health,' a Facebook post by Pasadena Human stated last week.
Staff minimized their contact with the injured animal while keeping up treatments and allowing the wounds to heal.
'We are so proud of our staff for providing top-notch care while keeping wildlife wild,' the post read.
After showing the ability to walk comfortably without the bandages, the bobcat was placed at the California Wildlife Center to continue its recovery in an outdoor space before hopefully being returned to the wild.
'The Eaton Fire had a devastating impact on wild animals, but being a part of their recovery gives us hope for the future of our local ecosystem,' Pasadena Humane stated.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
an hour ago
- Time Business News
Have You Seriously Considered The Option Of Orale Steroïden?
Steroid tablets may cause side-effects if taken for an extended period, such as osteoporosis and weight gain. You can minimize these side effects by taking calcium and vitamin D supplements, exercising regularly and refraining from smoking. Always carry with you a red or blue steroid emergency card provided by the person prescribing or dispensing your medicine, which outlines your dosage and medical condition to healthcare providers. Trustworthiness Online purchasing of steroids offers convenience, yet also poses certain risks to buyers' health and legal repercussions. Furthermore, counterfeit or unregulated products could be purchased. Therefore, buyers should ensure their vendors are legitimate by doing a detailed investigation and reviewing customer feedback as well as looking for professional website designs, secure payment options and transparent shipping policies from them. Steroids are powerful substances that can dramatically change how the body functions if taken under medical guidance and with other substances. If taken alone or taken by people not familiar with them, however, steroids can be potentially lethal. Google-owned YouTube and Facebook make it easy for potential steroid users to obtain appearance and performance-enhancing drugs (APEDs) without prescriptions, with searches for specific names of APEDs leading to videos providing contact details and instructions on purchasing them; other searches pointed towards bodybuilding or fitness model websites hosting content about steroids containing relevant terms relating to them. In addition, most websites did not present accurate information about use or risks and declined legal responsibility when selling illegal substances – all making life easy for steroid buyers. Customer service Purchase of steroids online requires taking into consideration several aspects to ensure its legality and safety, such as regional regulations, product authenticity and effectiveness, payment security measures and shipping policies. Users also often evaluate customer service by testing responsiveness and helpfulness of support teams. Steroids may be illegally used to enhance athletic performance, such as marathon running or swimming. Unfortunately, long-term or high dose use of these substances can have adverse side effects; to ensure safety it's important to consult a doctor first when considering taking steroids. As mentioned previously, steroids may interact with certain medicines, increasing your risk of side-effects. This is particularly relevant if taken in combination with NSAIDs that cause stomach ulcers; additionally, steroids can make you less sensitive to pain – this could pose problems if recovering from surgery or experiencing injury and this could result in serious health complications if left unchecked. Payment options Steroids may help treat flare-ups of rheumatoid arthritis, lupus or gout. Steroids can be taken in various forms; from tablets to liquids or creams or injections. Some individuals experience side effects from taking steroids; usually mild and they subside once treatment stops; this is more likely to happen when dosage levels are increased or taken for extended periods. Your treating provider will monitor your symptoms closely and may adjust dosage if symptoms worsen over time. Steroid tablets often cause more side effects than creams or injections because they enter the bloodstream, where they can have widespread impact. Steroid tablets may lead to weight gain and increased appetite; increase infection risks; raise pre-diabetes risks and bolster diabetes or pre-diabetes risks; slow growth rates among children or teenagers and require periodic height checks for those taking them; these adverse reactions must all be carefully considered before choosing which form of treatment would work best. Some individuals combine multiple anabolic steroids together, or 'stack', in order to enhance their effects. Others may 'pyramid' their use by gradually increasing doses over a period of time before stopping for a time so their bodies can recover. Product availability Steroids are powerful tools that can help increase muscle mass, boost strength, and enhance performance. But to avoid unwanted side effects and legal complications, orale steroïden must only be purchased from reliable licensed providers like myroidshop1 net/nl/. Steroids carry potential side effects and may even be illegal in certain countries, making it essential to understand the various legal implications when purchasing online. Doing your research thoroughly on this subject will enable you to make wiser purchase decisions while avoiding potential legal ramifications. Dianabol, Clenbuterol and Trenbolone are among the most widely available anabolic steroids on the market. All three compounds are known to accelerate muscle growth and fat loss and can be found in high doses on the market. Be wary of untrustworthy suppliers who sell counterfeit or substandard steroids that could pose health risks to users. TIME BUSINESS NEWS
Yahoo
12 hours ago
- Yahoo
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO
Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer (mPDAC) treated with elraglusib CHICAGO and FORT WORTH, Texas, June 20, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) ('Actuate' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced biomarker data from a recent poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting from the Phase 2 (Actuate-1801 Part 3B) trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line metastatic pancreatic adenocarcinoma (mPDAC). The study demonstrated the use of machine learning and statistical models to predict overall survival (OS) based on pre-dose plasma biomarkers. The poster described an analysis of 40 cytokines, chemokines, soluble cell receptors, and growth factors (CCSGs) from plasma samples obtained prior to treatment from all patients enrolled in Actuate-1801 Part 3B. The analysis identified 7 biomarkers as uniquely significant predictors of favorable survival in the elraglusib-treated cohort, including one, CXCL2, with an inverse survival trend compared to the GnP control arm. This indicates that in patients not treated with elraglusib, high CXCL2 was unfavorable, but this trend is reversed with elraglusib treatment, highlighting the potential of elraglusib to favorably affect the immune microenvironment. Univariate analysis revealed strong predictive performance with CXCL2 emerging as a consistently reliable biomarker for survival across multiple cross-validation analyses. Elevated levels of CXCL2 and TRAIL were associated with improved OS, while lower levels of CCL3, IL-1α, IL-18, TGF-β, and TRAIL R3 were similarly linked to better survival. These signatures were combined into multivariate machine learning models that accurately predicted patients who would survive for greater than one year if treated with elraglusib and GnP. 'These results represent an important advance in our biomarker strategy,' said Daniel Schmitt, President & Chief Executive Officer of Actuate. 'They support the ability to use simple, non-invasive blood-based markers to potentially identify patients more likely to benefit from elraglusib. The pre-dose biomarker signatures identified in the 1801 Part 3B study, particularly involving high CXCL2 and low TGF-β, CCL3, and IL-18, which were all associated with a survival benefit, suggests that elraglusib may exert pleiotropic immunomodulatory effects regulating cytotoxic T cells, NK cells and cells of the myeloid lineage including macrophages and neutrophils. Crosstalk between components of the immune system support the growing body of evidence that elraglusib enhances immune response mechanisms critical to its antitumor efficacy.' 'The application of unbiased mathematical and machine learning models allowed us to pinpoint the strongest biomarker signals free from pre-conceived notions of elraglusib's mechanisms. What is so exciting about this project is that the unbiased approach aligns with prior mechanistic studies. The congruence of our clinical data analytics and the preclinical research combined with the strength of our predictive models gives us confidence that these biomarkers could be extremely beneficial in identifying the right patients at the right time,' said Taylor Weiskittel, MD, Ph.D., the lead author on this study. 'We look forward to applying this approach to guide the development of elraglusib in mPDAC as well as other advanced cancer indications in the future.' The company plans to test the identified biomarkers prospectively in future trials. Additional efforts will focus on optimizing sequential univariate combinations for patient stratification, refining multivariate machine learning models for predictive accuracy, and comparing these approaches head-to-head. About Actuate Therapeutics, Inc. Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate's lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function. For additional information, please visit the Company's website at Forward-Looking Statements This press release contains forward-looking statements about us, including our and other parties' clinical trials and development plans, and our industry. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'ongoing,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would,' or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements related to present facts or current conditions or of historical facts, contained in this press release are forward-looking statements. Accordingly, these statements involve estimates, assumptions, substantial risks and uncertainties which could cause actual results to differ materially from those expressed in them, including but not limited to that preliminary and unpublished data including biomarker studies may be subject to change and further interpretation following the availability of more data or following a more comprehensive review of the data and should not be relied upon as a final analysis; clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, results of prior preclinical studies, early clinical trials, machine learning and predictive modeling are not necessarily predictive of future results and may not correlate with improved responses, and elraglusib may not achieve positive clinical results or favorable preclinical results or receive regulatory approval on a timely basis, if at all; that we may not successfully enroll additional patients or establish or advance plans for further development, including through conversations with the FDA or EMA and the standards such bodies may impose for such development; that elraglusib could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials or result in other negative consequences; our reliance on third parties to conduct our non-clinical studies and our clinical trials; our reliance on third-party licensors and ability to preserve and protect our intellectual property rights; that we face significant competition from other biotechnology and pharmaceutical companies; our ability to fund development activities, including because our financial condition raises substantial doubt as to our ability to continue as a going concern and we require additional capital to finance our operations beyond the second quarter of fiscal year 2025, and a failure to obtain this necessary capital in the near term on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations. In addition, any forward-looking statements are qualified in their entirety by reference to the factors discussed under the heading 'Item 1A. Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 13, 2025, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 15, 2025, and other filings with the SEC. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Unless legally required, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events. Investor Contact Mike MoyerManaging DirectorLifeSci Advisors, LLCmmoyer@ Media Contact Ignacio Guerrero-Ros, Ph.D., or David SchullRusso Partners, 717-2310 or (646) 942-5604Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 hours ago
- Yahoo
Astera Labs (ALAB) Partners with Alchip Technologies to Develop AI Infrastructure
Astera Labs, Inc. (NASDAQ:ALAB) is one of the 11 must-buy AI stocks analysts are betting on. On June 16, the company inked a strategic collaboration with Alchip Technologies. The two are joining forces to accelerate the development of next-generation AI infrastructure. A close-up of a technician's hands working on an advanced semiconductor substrate. The collaboration will merge Alchip's custom ASIC development capabilities with Astera Labs' comprehensive connectivity portfolio. The integrated solution will deliver interoperable solutions for hyperscalers building next-generation AI infrastructure: Astera Labs and its partner hope to streamline purpose-built AI infrastructure that meets performance demand for next-generation applications. The strategic partnership should benefit hyperscalers by providing validated complete solutions integrating Astera Labs' Intelligent Connectivity Platform. It will also promote industry innovation for next-generation AI connection standards such as Ethernet, NVLink Fusion, and UALinkTM. Astera Labs, Inc. (NASDAQ:ALAB) provides semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform integrates mixed-signal products, microcontrollers, sensors, and the COSMOS software suite for large-scale system management. While we acknowledge the potential of ALAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best Healthcare Stocks to Buy Now and 10 Stocks Analysts Are Upgrading Today. Disclosure: None. Sign in to access your portfolio
